Merck's acquisition of Cidara Therapeutics for $9.2 billion focuses on CD388, a promising antiviral for influenza prevention.

The FDA has granted full approval to Kura Oncology and Kyowa Kirin’s Komzifti (ziftomenib), marking the first FDA-approved once-daily, oral menin inhibitor for adults with relapsed or refractory (R/R) ...

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how events from the past ...

Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its ...

New regulatory initiatives in 2026 impacted DE&I, creating challenges and opportunities for the pharmaceutical industry. Companies are urged to integrate DE&I into core operations, focusing on patient ...

In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA ...